Caricamento...
Relapsed Myasthenia Gravis after Nivolumab Treatment
Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although “new-onset” autoimmune diseases are well-known immune-related adverse events, whether or not nivoluma...
Salvato in:
| Pubblicato in: | Intern Med |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
The Japanese Society of Internal Medicine
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6064691/ https://ncbi.nlm.nih.gov/pubmed/29434145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.9153-17 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|